Minimal residual disease in HCL 31
11. Tallman MS, Hakimian D, Kopecky KJ, et al. Minimal progressed hairy cell leukemia. Haematologica 2001;86:1046–
residual disease in patients with hairy cell leukemia in 1050.
complete remission treated with 2-chlorodeoxyadenosine or 26. Angelopoulou MK, Pangalis GA, Sachanas S, et al. Outcome
2-deoxycoformycin and prediction of early relapse. Clin and toxicity in relapsed hairy cell leukemia patients treated
Cancer Res 1999;5:1665–1670. with rituximab. Leuk Lymphoma 2008;49:1817–1820.
12. Ginaldi L, De Martinis M, Matutes E, et al. Levels of 27. Thomas DA, O’Brien S, Bueso-Ramos C, et al. Rituximab in
expression of CD19 and CD20 in chronic B cell leukaemias. J relapsed or refractory hairy cell leukemia. Blood 2003;102:
Clin Pathol 1998;51:364–369. 3906–3911.
13. Anderson KC, Bates MP, Slaughenhoupt BL, et al. Expres- 28. Giles FJ, Vose JM, Do KA, et al. Circulating CD20 and CD52
sion of human B cell-associated antigens on leukemias and in patients with non-Hodgkin’s lymphoma or Hodgkin’s
lymphomas: a model of human B cell differentiation. Blood disease. Br J Haematol 2003;123:850–857.
1984;63:1424–1433. 29. Weng WK, Levy R. Two immunoglobulin G fragment C
14. Einfeld DA, Brown JP, Valentine MA, et al. Molecular receptor polymorphisms independently predict response to
cloning of the human B cell CD20 receptor predicts a rituximab in patients with follicular lymphoma. J Clin Oncol
hydrophobic protein with multiple transmembrane domains. 2003;21:3940–3947.
Embo J 1988;7:711–717. 30. Cervetti G, Galimberti S, Andreazzoli F, et al. Rituximab as
15. Valentine MA, Meier KE, Rossie S, et al. Phosphorylation treatment for minimal residual disease in hairy cell leukaemia.
of the CD20 phosphoprotein in resting B lymphocytes. Eur J Haematol 2004;73:412–417.
Regulation by protein kinase C. J Biol Chem 1989;264: 31. Cervetti G, Galimberti S, Andreazzoli F, et al. Rituximab as
11282–11287. treatment for minimal residual disease in hairy cell leukaemia:
16. Venugopal P, Sivaraman S, Huang XK, et al. Effects of extended follow-up. Br J Haematol 2008;143:296–298.
cytokines on CD20 antigen expression on tumor cells from 32. Di Gaetano N, Xiao Y, Erba E, et al. Synergism between
patients with chronic lymphocytic leukemia. Leuk Res fludarabine and rituximab revealed in a follicular lymphoma
2000;24:411–415. cell line resistant to the cytotoxic activity of either drug alone.
17. Tedder TF, Boyd AW, Freedman AS, et al. The B cell surface Br J Haematol 2001;114:800–809.
molecule B1 is functionally linked with B cell activation and 33. Ravandi F, Jorgensen JL, O’Brien SM, et al. Eradication of
differentiation. J Immunol 1985;135:973–979. minimal residual disease in hairy cell leukemia. Blood
18. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells 2006;107:4658–4662.
in vivo by a chimeric mouse human monoclonal antibody to 34. Thomas DA, Ravandi F, Kantarjian H. Monoclonal antibody
CD20. Blood 1994;83:435–445. therapy for hairy cell leukemia. Hematol Oncol Clin North
19. O’Brien SM, Kantarjian H, Thomas DA, et al. Rituximab Am 2006;20:1125–1136.
dose-escalation trial in chronic lymphocytic leukemia. J Clin 35. Quigley MM, Bethel KJ, Sharpe RW, et al. CD52 expression
Oncol 2001;19:2165–2170. in hairy cell leukemia. Am J Hematol 2003;74:227–230.
20. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a 36. Fietz T, Rieger K, Schmittel A, et al. Alemtuzumab (Campath
thrice weekly dosing schedule in B-cell chronic lymphocytic 1H) in hairy cell leukaemia relapsing after rituximab treat-
leukemia and small lymphocytic lymphoma demonstrates ment. Hematol J 2004;5:451–452.
clinical activity and acceptable toxicity. J Clin Oncol 37. Leonard JP, Coleman M, Ketas JC, et al. Epratuzumab, a
2001;19:2153–2164. humanized anti-CD22 antibody, in aggressive non-Hodgkin’s
21. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to lymphoma: phase I/II clinical trial results. Clin Cancer Res
fludarabine may prolong progression-free survival and overall 2004;10:5327–5334.
survival in patients with previously untreated chronic lym- 38. Leonard JP, Schuster SJ, Emmanouilides C, et al. Durable
phocytic leukemia: an updated retrospective comparative complete responses from therapy with combined epratuzumab
analysis of CALGB 9712 and CALGB 9011. Blood 2005; and rituximab: final results from an international multicenter,
105:49–53. phase 2 study in recurrent, indolent, non-Hodgkin lymphoma.
22. Tam CS, O’Brien S, Wierda W, et al. Long-term results of the Cancer 2008;113:2714–2723.
fludarabine, cyclophosphamide, and rituximab regimen as 39. Castillo J, Milani C, Mendez-Allwood D. Ofatumumab, a
initial therapy of chronic lymphocytic leukemia. Blood second-generation anti-CD20 monoclonal antibody, for the
2008;112:975–980. treatment of lymphoproliferative and autoimmune disorders.
23. Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the Expert Opin Investig Drugs 2009;18:491–500.
treatment of cladribine-failed patients with hairy cell leukemia. 40. Osterborg A, Kipps TJ, Mayer J, et al. Ofatumumab (HuMax-
Blood 2003;102:810–813. CD20), a novel CD20 monoclonal antibody, is an active
24. Hagberg H, Lundholm L. Rituximab, a chimaeric anti-CD20 treatment for patients with CLL refractory to both fludarabine
monoclonal antibody, in the treatment of hairy cell leukaemia. and alemtuzumab or bulky fludarabine-refractory disease:
Br J Haematol 2001;115:609–611. results from the planned interim analysis of an international
25. Lauria F, Lenoci M, Annino L, et al. Efficacy of anti- pivotal trial. Blood (Suppl) 2008;112(Abstract no. 328):126–
CD20 monoclonal antibodies (Mabthera) in patients with 127.
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46